COX-2 inhibition in upper aerodigestive tract tumors

Seminars in Oncology

Volumn 31, Issue SUPPL. 7, 2004, Pages 30-35

  Altorki, Nasser K ^a,b   Subbaramaiah, Kotha ^a   Dannenberg, Andrew J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CISPLATIN; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; IRINOTECAN; METHOTREXATE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; PLATINUM; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; ROFECOXIB; TAXANE DERIVATIVE; TILMACOXIB;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CHEMOPROPHYLAXIS; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; ESOPHAGUS CANCER; FEASIBILITY STUDY; HEAD CANCER; HUMAN; INFLAMMATION; LEUKOPENIA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR MECHANICS; NASOPHARYNX TUMOR; NECK CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TUMOR GROWTH; ULCER;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTICARCINOGENIC AGENTS; BARRETT ESOPHAGUS; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HEAD AND NECK NEOPLASMS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; STOMACH NEOPLASMS;

EID: 3042759696     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seminoncol.2004.03.043     Document Type: Review

References (37)

1. Jemal A., Murray T., Samuels A., et al. Cancer statistics, 2003. CA Cancer J Clin. 53:2003;5-26
2. American Cancer Society. Cancer Facts & Figures 2002. 2002;American Cancer Society, Atlanta, GA
3. Karpeh M.S., Kelsen D.P., Tepper J.F. Cancer of the stomach. Devita V.T., Helman S., Rosenberg S.A. Cancer Principles and Practice of Oncology. 2001;1092-1126 Lippincott Williams & Wilkins, Philadelphia, PA
4. Dannenberg A.J., Altorki N.K., Boyle J.O., et al. Cyclooxygenase-2 A pharmacological target for the prevention of cancer. Lancet Oncol. 2:2001;544-551
5. Chan G., Boyle J.O., Yang E.K., et al. Cyclooxygenase-2 expression is upregulated in squamous cell carcinoma of the head and neck. Cancer Res. 59:1999;991-994
6. Ristimaki A., Honkanen N., Jankala H., et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57:1997;1276-1280
7. Wilson K.T., Fu S., Ramanujuan K.S., et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 58:1998;2929-2934
8. Sung J.J.Y., Leung W.K., Go M.Y.Y., et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol. 157:2000;729-735
9. Δ716 knockout mice by inhibition of cyclooxygenase-2. Cell. 87:1996;803-809
10. Liu C.H., Chang S.H., Narko K., et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 276:2001;18563-18569
11. Shiotani H., Denda A., Yamamoto K., et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res. 61:2001;1451-1456
12. 2 in human head and neck xenograft tumors. Cancer Res. 62:2002;6706-6711
13. Nishimura G., Yanoma S., Mizuno H., et al. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res. 90:1999;1152-1162
14. Buttar N.S., Wang K.K., Leontovich O., et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology. 122:2002;1101-1112
15. Li Z., Shimada Y., Kawabe A., et al. Suppression of N- nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor. Carcinogenesis. 22:2001;547-551
16. Sawaoka H., Kawano S., Tsuji S., et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol. 274:1998;G1061-1067
17. Trifan O.C., Durham W.F., Salazar V.S., et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. 62:2002;5778-5784
18. Milas L., Kishi K., Hunter N., et al. Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst. 91:1999;1501-1504
19. Wiese F.W., Thompson P.A., Kadlubar F.F. Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis. 21:2001;5-10
20. 2 in human colon cancer cells. Cancer Res. 58:1998;362-366
21. Lagugren J., Bergstrom R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 340:1999;825-831
22. 2 inhibits TNF-α release via a mechanism involving IL-10. J Immunol. 154:1995;3383-3390
23. Tsuji M., Kawano S., Tsuji S., et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716
24. Tsuji M., Kawano S., DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 94:1997;3336-3340
25. Dohadwala M., Luo J., Zhu L., et al. Non-small cell lung cancer cyclooxygenase-2 dependent invasion is mediated by CD44. J Biol Chem. 276:2001;20809-20812
26. Gallo O., Franchi A., Magnelli L., et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia. 3:2001;53-61
27. Glück S., Mackinnon J., Lau H., et al. Metronomic therapy in recurrent and metastatic chemoresistant SCCHN Data from a pilot study. Proc Am Soc Clin Oncol. 22:2003;513. (abstr)
28. Buskens C.J., Van Rees B.P., Sivula A., et al. Prognostic significance of elevated cyclooxygenase-2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology. 122:2002;1800-1807
29. Buttar N.S., Wang K.K., Anderson M.A., et al. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium an in vitro study. J Natl Cancer Inst. 94:2002;422-429
30. Souza R.F., Shewmake K., Beer D.G., et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 60:2000;5767-5772
31. Kaur B.S., Khamnehei N., Iravani M., et al. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology. 123:2002;60-67
32. Enzinger P.C., Mamon H., Bueno R., et al. Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. Proc Am Soc Clin Oncol. 22:2003;361. (abstr)
33. Mantravadi R.V.P., Fineberg N., Ansari R., et al. A phase II study of cisplatin, 5-fluorouracil (5-FU), radiation (RT) and celecoxib in patients with resectable esophageal cancer (EC) Preliminary results from the Hoosier Oncology Group (HOG). Proc Am Soc Clin Oncol. 22:2003;291. (abstr)
34. Lim H.Y., Joo H.J., Choi J.H., et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res. 6:2000;519-525
35. Murata H., Kawano S., Tsuji S., et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol. 94:1999;451-455
36. Saukkonen K., Tomasetto C., Narko K., et al. Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. Cancer Res. 63:2003;3032-3036
37. Uefuji K., Ichikura T., Shinomiya N., et al. Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines. Anticancer Res. 20:2000;4279-4284